natgillin/translations-raw huggingface dataset:
Protection and deprotection in the processes below may be carried out by procedures generally known in the art (see, for example, T. W. Greene & P. G. M. Wuts, “Protecting Groups in Organic Synthesis”, 3rd Edition, Wiley, 1999). 
Zaštita i uklanjanje zaštitne skupine u postupcima niže mogu se provesti primjenom postupaka koji su općenito poznati u struci (vidjeti, npr., T.W.Greene and P.G.M.Wuts, "Protecting Groups in Organic Synthesis", 3"! Edition, Wiley, 1999).
DEFINITIONS The following definitions apply to the terms as used throughout this specification, unless otherwise limited in specific instances. 
DEFINICIJE Slijedeće definicije se primjenjuju na termine koji se upotrebljavaju u ovoj specifikaciji, osim ako nije drugačije ograničeno u specifičnim primjerima.
In the uses of the present invention, the dihydrogenphosphate salt and crystalline hydrates herein described in detail can form the active pharmaceutical ingredient, and are typically administered in admixture with suitable pharmaceutical diluents, excipients or carriers (collectively referred to herein as 'carrier' materials) suitably selected with respect to the intended form of administration, that is, oral tablets, capsules, elixirs, syrups and the like, and consistent with conventional pharmaceutical practices. 
Kod korištenja predmetnog izuma, dihidrogenfosfatna sol i kristalni hidrati ovdje detaljno opisani, mogu biti aktivan farmaceutski sastojak, te se tipično daju u smjesi sa prikladnim farmaceutskim razrjeđivačima, ekscipijentima ili nosačima (kolektivno ovdje nazvani 'nosači' materijali) pogodno odabrani u skladu s namjeravanim oblikom davanja, to jest, tabletama, kapsulama, eliksirima, sirupima i slično, te u skladu sa konvencionalnim farmaceutskim postupcima.
The method as claimed in claim 2 wherein at least 99.9% of the 227Ac loaded onto the resin in step ii) is recovered in step x). 
Metoda u skladu s patentnim zahtjevom 2 pri čemu je najmanje 99,9% 227Ac nanesenog na smolu u koraku ii) obnovljeno u koraku x).
The kit according to claim 14 further comprising instructions for use of the compound in the treatment of cancer, and more preferably a cancer selected from lung cancer, including non-small cell lung cancer and small cell lung cancer, colon cancer, colorectal cancer, breast cancer, pancreas cancer, sarcoma, ovarian cancer and gastric cancer. 
Komplet prema patentnom zahtjevu 11 koji dalje sadrži uputstva za upotrebu sjedinjenja u liječenju raka, i poželjnije raka odabranog od raka pluća, uključujući rak pluća malih stanica i rak pluća nemalih stanica, raka debelog crijeva, kolorektalnog raka, raka dojke, raka gušterače, sarkoma, raka jajnika, i raka želuca.
A composition according to any one of items 1 to 3 wherein the inflammatory bowel disease is recurrence of ileal lesions after surgery, for example surgery to remove at least a part of the small intestine in CD patients. 
Spoj za uporabu sukladno bilo kojem od patentnih zahtjeva od 1 do 3, pri čemu kronična upalna bolest crijeva je Chronova bolest ili ulcerozni kolitis ili ponavljanje crijevnih lezija nakon operacije, na primjer operacija odstranjivanja barem jednog dijela tankog crijeva kod Chronovih bolesnika.
The method of claim 1, wherein the immune disorder is inflammatory bowel disease. 
postupku liječenja imunološkog poremećaja, pri čemu je imunološki poremećaj autoimuna bolest; ili
The antibody or a-synuclein binding fragment thereof of claim 1, wherein the VH region comprises the amino acid sequence of SEQ ID NO: 9 and the VL region comprises the amino acid sequence of SEQ ID NO: 12. 
Protutijelo ili njegov fragment koji veže a-sinuklein u skladu s patentnim zahtjevom 1, naznačen time da VH regija obuhvaća aminokiselinske odsječke od SEQ ID NO: 9 i VL regija sadržava aminokiselinske odsječke od SEQ ID NO: 12.
Buffer is oxygenated with 95% 02/5% C02 for 10 min at 37° C. and pH is adjusted 7.4. 
Bufer se oksidira s 95% O2/5% CO, 10 minuta na 37 stupnjeva C i pH se adaptira s 7.4.
is cycloalkyl, aryl, heterocyclyl or heteroaryl, where R4 is optionally substituted with one to three groups selected from Q1; 
R je cikloalkil, aril, heterociklil ili heteroaril, pri čemu je R* opcionalno supstituiran s jednom do tri grupe izabrane iz
The compound of claim 3, wherein R2 is unsubstituted methyl, and R3 is unsubstituted methyl. 
Spoj u skladu s patentnim zahtjevom 3, naznačen time što R2 je nesupstituirani metil i R3 je nesupstituirani metil.
The composition of claim 1, wherein the composition comprises natalizumab at a concentration of 150 mg/ml, a sodium phosphate buffer at a concentration of 10 mM, sodium chloride at a concentration of 140 mM, and polysorbate 80 in an amount of 0.04% (w/v), and wherein the composition has pH of 5.5 to 6.5. 
Pripravak prema zahtjevu 1, naznačen time što pripravak sadrži natalizumab u koncentraciji od 150 mg/ml, pufer natrijevog fosfata u koncentraciji od 10 mM, natrijev klorid u koncentraciji od 140 mM i polisorbat 80 u količini od 0,04 % (m/v), te pri čemu pripravak ima pH od 5,5 do 6,5.
The plane of pivot axis 36 may be generally parallel to first and/or second side surfaces 14 and 16 . 
Ravnina osi vrtnje 36 može općenito biti paralelna prvoj i/ili drugoj površini 14 i 16.
Compounds of the formula I according to claim 1 and pharmaceutically acceptable salts, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, for the use for the treatment and/or prevention of cancer, multiple sclerosis, cardiovascular diseases, central nervous system injury and different forms of inflammation. 
Spojevi s formulom I prema zahtjevu 1 i njihove farmaceutski prihvatljive soli, solvati, tautomeri i stereoizomeri, uključujući njihove smjese u svim omjerima, naznačeni time da su za uporabu za liječenje i/ili prevenciju raka, multiple skleroze, kardiovaskularnih bolesti, ozljede središnjeg živčanog sustava 1 različitih oblika upala.
8) wherein the residue denoted by the symbol X17-18 is a dipeptide residue of a pseudoproline; said amino acid residues optionally including side chain protection. 
8) gdje ostatak označen simbolom X!" je dipeptidni ostatak pseudoprolina; navedeni amino kiselinski ostaci po izboru uključuju zaštitu bočnog lanca.
The diluent reacts in air with the unsaturated bonds in the resin. 
Sredstvo za razrjeđivanje reagira na zraku s nezasićenim vezama u smoli.
represents a branched or unbranched alkylene radical with from 1 to 12 C atoms or a substituted or unsubstituted alkarylene radical with from 6 to 24 C atoms, 
predstavlja razgranati ili nerazgranati alkilenski radikal sa 1 do 12 C atoma ili supstituirani ili nesupstituirani alkarilenski radikal sa 6 do 24 C atoma,
A process according to claim 32 wherein the coupling agent is 1-(3-dimethylaminopropyl)-ethylcarbodiimide hydrochloride (EDCI). 
Postupak u skladu s patentnim zahtjevom 33, naznačen time što je kondenzacijsko sredstvo 1,1'- karbonildiimidazol (CDI) 1li 1-(3-dimetilaminopropiljetilkarbodiimid-hidroklorid (EDCI).
An anti-CD20 antibody formulation for use according to claim 1, the formulation comprising an anti-CD20 antibody in the concentration range of 50-300 mg/mL, 50 mM sodium acetate, 51 mM sodium chloride, 1% arginine free base, 0.05 mM EDTA, 0.02% polysorbate 80, and adjusted to pH 5.5. 
Formulacija protutijela anti-CD20, naznačena time, da obuhvaća ofatumumab u rasponu koncentracije od 20 do 300 mg/mL, pri čemu formulacija nadalje obuhvaća 50 mM natrijevog acetata, 51 mM natrijevog klorida, 1% slobodne baze arginina, 0,05 mM EDTA, 0,02% polisorbata 80, i namještena je na pH-vrijednost od 5,5.
A pharmaceutical combination, containing a compound according to any one of claims 1-13, or a pharmaceutically acceptable salt or an isomer thereof, and one or more therapeutic active substances, wherein said therapeutic active substance is selected from angiotensin II receptor antagonist or a pharmaceutically acceptable salt; HMG-Co-A reductase inhibitor or a pharmaceutically acceptable salt; calcium-channel blocker (CCB) or a pharmaceutically acceptable salt; dual angiotensin-convertion enzyme/neutral endopeptidase (ACE/NEP) inhibitor or a pharmaceutically acceptable salt; an antidiabetic drug; an antiobesic drug; aldosterone receptor block agent; endothelin receptor block agent; CETP inhibitor; Na-K-ATPase membrane pump inhibitor; B-adrenergic receptor inhibitor or a-adrenergic receptor blocking agent; neutral endopeptidase (NEP) inhibitor and inotropic agent. 
Farmaceutska kombinacija, koja sadrži spoj prema bilo kojem od zahtjeva 1-15, ili njegovu farmaceutski prihvatljivu sol, i jednu ili više terapeutski aktivnih tvari, pri čemu je spomenuta terapeutski aktivna tvar odabrana od antagonista angiotenzin II receptora ili farmaceutski prihvatljive soli; inhibitora HMG-Co-A reduktaze ili farmaceutski prihvatljive soli; blokatora kanala kalcija (CCB) ili farmaceutski prihvatljive soli; inhibitora dvostruke angiotenzin-pretvarajuće enzim/neutralne endopeptidaze (ACE/NEP) ili farmaceutski prihvatljive soli; antidijabetičkog lijeka; lijeka protiv gojaznosti; blokirajućeg agensa aldosteron receptora; blokirajućeg agensa endotelin receptora; CETP inhibitora; inhibitora Na-K-ATPaza membranske pumpe; inhibitora B-adrenergičnog receptora ili blokirajućeg agensa a-adrenergičnog receptora; inhibitora neutralne endopeptidaze (NEP) i inotropičnog agensa.
wherein Ar excludes substituted or unsubstituted indazol-3-yl and substituted or unsubstituted 1H-pyrazolo[3,4-b]pyridyl. 
i pri čemu Ar isključuje supstituirani ili nesupstituirani indazol-3-il i supstituirani ili nesupstituirani 1H-pirazolo[3,4-b]piridil.
An electrically heated smoking system according to any preceding claim, wherein the thermally insulating material (507) is provided on the electrically insulating substrate (101, 201, 301, 401, 501) in addition to the electrically conductive tracks. 
Električno grijani sustav za pušenje u skladu s patentnim zahtjevom 1, 2 1li 3, naznačen time što se jedna ili više električno vodljivih tračnica (203) nalazi s vanjske strane cijevi od električno izolirajuće podloge (201).
regenerate the special data packet with the end marker to be sent to the target eNB through the X2 interface, wherein the special data packet to be sent to the target eNB does not contain user data, and the end marker in the special data packet to be sent to the target eNB is set in the header of the special data packet to be sent to the target eNB to indicate that the special data packet is the last data packet to be sent from the source eNB to the target eNB. 
LTE mreža prema zahtjevu 5, naznačena time da je SGW konfiguriran da generira poseban paket podataka i šalje poseban paket podataka prema izvorišnom eNB nakon što SGW provede komutaciju puta; i izvorišni eNB je konfiguriran da regenerira specijalni paket podataka sa završnom oznakom u skladu sa posebnim paketom podataka poslanim od SGW i šalje regenerirani posebni paket podataka prema ciljnom eNB, pri čemu regenerirani posebni paket podataka ne sadrži pakete korisničkih podataka i nosi broj PDCP sekvence slijedećeg paketa korisničkih podataka koji se treba poslati od izvornog eNB.
Furthermore, it is preferred that the ground calcium carbonate and/or the precipitated calcium carbonate has a weight median particle diameter d50 value of from 0.1 to 50 um, preferably from 0.1 to 25 um, more preferably from 0.1 to 15 um and most preferably from 0.5 to 5 um, measured according to the sedimentation method. For example, the ground calcium carbonate particles and/or the precipitated calcium carbonate particles have a weight median particle diameter d50 value of 1.5 um. 
Hidrofobirani prirodni kalcijev karbonat i/ili hidrofobirani taložni kalcijev karbonat prema bilo kojem od zahtjeva 17 do 19, naznačen time da čestice prirodnog kalcijevog karbonata i/ili čestice taložnog kalcijevog karbonata imaju vrijednost medijana volumne raspodjele promjera čestica dso od 0.1 do 50 um, poželjno od 0.1 do 25 um, poželjnije od 0.1 do 15 um i najpoželjnije od 0.5 do 5 um, izmjereno prema postupku sedimentacije.
Conveniently, the compound of Formula VIII is reacted with a compound of the Formula IX in the presence of a protic solvent such as isopropanol, conveniently in the presence of an acid, for example a catalytic amount of an acid, under the conditions described above. 
Poželjno se spoj prikazan Formulom VIII stavlja u reakciju sa spojem prikazanim Formulom IX u prisutnosti protičkog otapala, poput izopropanola, prikladno u prisutnosti kiseline, na primjer katalitičke količine kiseline, pod gore navedenim uvjetima.
a compound of formula I is prepared wherein R3 and R4 are both hydrogen, herein represented by formula I-a, by an uracil to cytosine conversion reaction from a 2'-deoxy-2'-spirocyclopropyl uridine 1f to the corresponding 2'-deoxy-2'-spirocyclopropyl cytidine 1g, followed by removal of the protecting groups PG yielding compound I-a: 
priprema spoj sa formulom I pri čemu R3 i R4 su oba vodik, ovdje prikazano sa formulom I-a, pomoću reakcije konverzije uracila u citozin od 2'-deoksi-2'-spirociklopropil uridina 1f u odgovarajući 2'-deoksi-2'-spirociklopropil citidin 1g, nakon čega slijedi uklanjanje zaštitnih skupina PG da se dobije spoj I-a: [image]
The composition of embodiment 1, wherein the composition is for use in a method of treating or preventing a disease or condition selected from the group consisting of uveitis; cancer, such as breast cancer, lung cancer, liver cancer, colon cancer, or ovarian cancer; multiple sclerosis; arthritis, such as rheumatoid arthritis, osteoarthritis, psoriatic arthritis, or juvenile idiopathic arthritis; neuromyelitis optica (Devic's disease); ankylosing spondylitis; spondyloarthritis; psoriasis; systemic lupus erythematosus; inflammatory bowel disease, such as Crohn's disease or ulcerative colitis; celiac disease; asthma, such as allergic asthma or neutrophilic asthma; chronic obstructive pulmonary disease (COPD); scleritis; vasculitis; Behcet's disease; atherosclerosis; atopic dermatitis; emphysema; periodontitis; allergic rhinitis; and allograft rejection. 
Pripravak prema zahtjevu 1, naznačen time da je pripravak za upotrebu u postupku liječenja ili prevencije bolesti ili stanja koje se biraju iz skupine koja sadrži uveitis; rak, kao što je rak dojke, rak pluća, rak jetre, rak debelog crijeva, ili rak jajnika; multiple skleroza; artritis, kao što je reumatoidni artritis, osteoartritis, psorijazni artritis, ili juvenilni idiopatski artritis; neuromijelitis optika (Devicova bolest); ankilozirajući spondilitis; spondiloartritis; psorijaza; sistemski eritemski lupus; upalna bolest crijeva, kao što je Crohnova bolest ili ulcerativni kolitis; celijakija; astma, kao što je alergijska astma ili astma koja je posredovana neutrofilima; kronična opstruktivna plućna bolest (KOPB); skleritis; vaskulitis; Behcetova bolest; ateroskleroza; atopijski dermatitis; emfizem; periodontitis; alergijski rinitis; te odbacivanje alografta.
The method of clause 6, wherein the metallic nanoparticle or metallic nanoshell is selected from the group consisting of gold particles, silver particles, copper particles, platinum particles, cadmium particles, composite particles, gold hollow spheres, gold-coated silica nanoshells, and silica-coated gold shells. 
Postupak u skladu s patentnim zahtjevom 6, naznačen time što se metalnu nanočesticu ili metalnu nanoljusku bira iz skupine koju čine čestice zlata, čestice srebra, čestice bakra, čestice platine, čestice kadmija, kompozitne čestice, šuplje kuglice od zlata, nanoljuske od silicijevog dioksida obložene zlatom, te zlatne ljuske obložene silicijevim dioksidom.
The therapeutic composition according to claim 57, wherein the cytotoxic conjugate comprises a humanized version of the murine antibody DS6 or an epitope-binding fragment thereof as the cell binding agent and DM1 or DM4 as the cytotoxic agent. 
Smjesa za liječenje prema zahtjevu 57, naznačena time što citotoksični konjugat obuhvaća humaniziranu verziju mišjeg protutijela DS6 ili njegov fragment koji se veže za epitop kao tvar koja se veže za stanicu te DM1 ili DM4 kao citotoksičnu tvar.
the suspension obtained by step (a) is sprayed onto the filler in a fluidized bed granulation and dried to form granules, 
suspenzija dobivena u koraku (a) se raspršuje na punilo u granulaciji s fluidiziranim slojem i suši da se dobiju granule,
extracting the diastolic signal from the received PCG signal using the received ECG signal. The method according to claim 10, further including the step of storing at least one of the received PCG signal, the received ECG signal, the extracted diastolic signal, the isolated S2 component, the estimated maximum frequency and the blood pressure estimate. 
Postupak prema zahtjevu 4, 5, 6, 7, ili 8, naznačen time da izdvajanje dijastoličkog signala sadrži korake: sinkroniziranog prijema PCG signala 1 signala elektrokardiograma (EKG); te izdvajanje dijastoličkog signala iz primljenog PCG signala korištenjem primljenog EKG signala.
One embodiment provides a process for preparing a compound of formula I-2: 
PATENTNI ZAHTJEVI 1. = Postupak dobivanja spoja formule I-2:
The method as claimed in claim 1, wherein said wash water is for a desalter of the crude oil processing system. 
Metoda temeljem bilo kojeg od zahtjeva 1 do 7, naznačena time što se navedena voda za ispiranje koristi u desalteru sustava za preradu sirove nafte.
has a ta half-life of about 15 seconds to about 12 hours, 
ima ta poluživot od oko 15 sekundi do oko 12 sati, i
the additional therapeutic agent is at least one selected from the group consisting of insulin or analogues thereof, glucocorticoids, cyclosporin, methotrexate, non-steroidal anti-inflammatory drugs (NSAIDs), TNF-a antagonists, IL-1 antagonists, IL-6 antagonists, and opioids; and/or 
(i) < dodatno terapeutsko sredstvo je najmanje jedno sredstvo odabrano iz grupe koja se sastoji od inzulina ili njegovih analoga, glukokortikosteroida, ciklosporina, metotreksata, nesteroidnih protuupalnih lijekova (NSAID), antagonista TNF-a, antagonista IL-1, antagonista IL-6 i opioida; i/ili
Of the method of preparing a compound of formula (II), as set forth above in the Summary of the Invention, or a pharmaceutically acceptable salt thereof, as a single stereoisomer or enantiomer or a mixture thereof, one embodiment is the method which further comprises the preparation of a compound of formula (15), or a pharmaceutically acceptable salt thereof, wherein a compound of formula (14): 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se dodatno sastoji u razdvajanju spoja formule (1), ili njegove farmaceutski prihvatljive soli, u obliku smjese enantiomera, u uvjetima pogodnim za dobivanje spoja formule (I-$): ili njegove farmaceutski prihvatljive sol, i spoja formule (I-R): O O |
A receiver comprising means for implementing the method according to one or more of claims 12 to 17. 
Prijemnik koji sadrži sredstva za implementaciju metode prema jednom ili više patentnih zahtjeva 12 do 17.
The pharmaceutical composition of claim 6 further comprising a pharmaceutically acceptable carrier. 
Farmaceutska smjesa prema zahtjevu 6 koja dalje sadrži farmaceutski prihvatljivi nosač.
A vaccine comprising an influenza virus antigen, wherein the vaccine contains no mercurial preservative, no antibiotic, no formaldehyde and no egg-derived materials. 
Sterilno cjepivo koje sadrži inaktivirani antigen virusa influence, naznačeno time da cjepivo ne sadrži konzervanse sa živom, ne sadrži antibiotik, ne sadrži formaldehid 1 ne sadrži materijale dobivene od jaja.
A method of forming a collapsible tube container comprising a side-seam weld or join, the method comprising the steps of: taking at least one strip of a blown film multi-layer polymeric material having a thickness of between 150 and 350 microns, more preferably of between 200 and 300 microns, each layer of the multi-layer polymeric material having a substantially similar or balanced molecular orientation profile; 
Postupak izrade fleksibilne ambalažne tube sa bočnim sučeonim šavom ili spojem naznačena time što se sastoji iz slijedećih koraka: uzimanje najmanje jedne trake puhanog filma višeslojnog polimernog materijala debljine od 150 um do 350 um, optimalno od 200 um do 300 um, čiji se svaki sloj odlikuje sličnim ili uravnoteženim profilom prostorno orijentacije molekula; oblikovanje spomenute trake višeslojnog polimernog materijala u duguljastu ambalažnu tubu koja se dobija preklapanjem obodnih bridova trake i zavarivanje ili spajanje preklopljenih bridova trake.
According to a first aspect of the invention there is provided a pharmaceutical formulation comprising an active agent in solid dispersion with a matrix polymer, wherein the active agent is 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one or a salt or solvate thereof, and the matrix polymer exhibits low hygroscopicity and high softening temperature. 
HR P20161154 T1 PATENTNI ZAHTJEVI mana» Farmaceutska formulacija koja sadrži aktivnu tvar u krutoj disperziji s matričnim polimerom, naznačena time da aktivna tvar je 4-[3-(4-ciklopropankarbonil-piperazin-1-karbonil)-4-fluoro-benzil]-2H-ftalazin-1-on ili njegova sol ili solvat, te matrični polimer ispoljava nisku higroskopnost i visoku temperaturu omekšavanja.
It is described an exemplary process for preparing Compound 1: said process comprises the steps of: cyclizing Compound 2 in a first solvent at an elevated temperature wherein R5 and R6 are each independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, alkylaryl, arylalkyl, heterocyclic and heteroaryl groups, or R5 and R6, together with the nitrogen to which they are attached, form a 3- to 6-membered heterocyclic compound containing 1-4 heteroatoms, to produce a first mixture of exo isomers said isomers having a trans-[5,6]-ring-junction and endo isomers: 
(a) ciklizacije Spoja 2 u prvom otapalu, na povišenoj temperaturi gdje svakog od Rs i Rs se neovisno bira iz skupine koju čine H, alkilne, alkenilne, alkinilne, alkoksi, cikloalkilne, arilne, alkilarilne, arilalkilne, heterocikličke i heteroarilne skupine, ili Rs i R4, zajedno s dušikom na kojeg su vezani, tvore 3- do 6-eročlani heterociklički spoj s 1-4 heteroatoma, kako bi se dobilo prvu smjesu exo-izomera gdje navedeni izomeri imaju zrans-[5,6]-vezu u prstenu; i endo-izomera:
The solid oral extended release pharmaceutical dosage form of any one of claims 1 to 5, wherein the active agent is oxycodone hydrochloride and wherein a dosage form comprising 10 mg of oxycodone hydrochloride when tested in a comparative clinical study is bioequivalent to a reference tablet containing 10 mg of oxycodone hydrochloride in a matrix formulation containing: 
Oralni farmaceutski oblik doziranja u krutom stanju sa produljenim otpuštanjem prema zahtjevu 1, naznačen time da oblik doziranja sadrži 10 mg oksikodon hidroklorida kada je ispitivan u komparativnoj kliničkoj studiji je sa referentnom tabletom koja sadrži 10 mg oksikodon hidroklorida u matričnoj formulaciji koja sadrži:
The placental stem cells for use according to claim 8, wherein said anti-inflammatory antibody is Infliximab. 
Matične stanice posteljice za uporabu u skladu s patentnim zahtjevom 8, naznačenu time što navedeno protuupalno antitijelo jest Infliksimab.
A powder according to claim 20 wherein the anticholinergic/antimuscarinic agent is selected from the group of ipratropium bromide, oxytropium bromide, tiotropium bromide, glycopyrrolate bromide and its enantiomers. 
Praškasta formulacija prema patentnom zahtjevu 9, naznačeno time da je antikolinergik ili antimuskarinsko sredstvo koje je antagonist M3-receptora odabrano iz skupine koju čine ipratropijev bromid, oksitropijev bromid, tiotropijev bromid, glikopirolat-bromid i njegovi enantiomeri.
The compound, pharmaceutically acceptable salt or pharmaceutical composition of claim 25, wherein the FXR mediated condition is selected from the group consisting of: 
Spoj, farmaceutski prihvatljiva sol ili farmaceutski sastav za upotrebu prema zahtjevu 11, pri čemu stanje posredovano sa FXR je izabrano iz grupe koja obuhvaća:
each anchor point is located below the normal waterline of the craft; 
svaka točka za sidrenje (12) je locirana ispod normalne linije vode plovila (2);